FOLH1 and neoplasm: Targeted therapies work by specifically blocking key molecular pathways that drive tumor growth and metastatic, including androgen receptor-targeted therapy, DNA damage response-targeted therapy, prostate-specific membrane antigen-targeted therapy, bone microenvironment-targeted therapy.